001     872541
005     20230117082039.0
024 7 _ |a 10.1111/1751-7915.13525
|2 doi
024 7 _ |a 1751-7907
|2 ISSN
024 7 _ |a 1751-7915
|2 ISSN
024 7 _ |a 2128/24433
|2 Handle
024 7 _ |a altmetric:73781372
|2 altmetric
024 7 _ |a pmid:31880860
|2 pmid
024 7 _ |a WOS:000504538600001
|2 WOS
037 _ _ |a FZJ-2020-00059
082 _ _ |a 610
100 1 _ |a Becker, Johanna
|0 0000-0001-9998-1846
|b 0
245 _ _ |a An Ustilago maydis chassis for itaconic acid production without by‐products
260 _ _ |a Oxford
|c 2020
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1583158631_24314
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a Biotechnologie 1
520 _ _ |a Ustilago maydis is a promising yeast for the production of a range of valuable metabolites, including itaconate, malate, glycolipids and triacylglycerols. However, wild‐type strains generally produce a potpourri of all of these metabolites, which hinders efficient production of single target chemicals. In this study, the diverse by‐product spectrum of U. maydis was reduced through strain engineering using CRISPR/Cas9 and FLP/FRT, greatly increasing the metabolic flux into the targeted itaconate biosynthesis pathway. With this strategy, a marker‐free chassis strain could be engineered, which produces itaconate from glucose with significantly enhanced titre, rate and yield. The lack of by‐product formation not only benefited itaconate production, it also increases the efficiency of downstream processing improving cell handling and product purity.
536 _ _ |a 581 - Biotechnology (POF3-581)
|0 G:(DE-HGF)POF3-581
|c POF3-581
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Hosseinpour Tehrani, Hamed
|0 P:(DE-Juel1)176855
|b 1
700 1 _ |a Gauert, Marc
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Mampel, Jörg
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Blank, Lars M.
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Wierckx, Nick
|0 P:(DE-Juel1)176653
|b 5
|e Corresponding author
773 _ _ |a 10.1111/1751-7915.13525
|g p. 1751-7915.13525
|0 PERI:(DE-600)2406063-X
|n 2
|p 350 - 362
|t Microbial biotechnology
|v 13
|y 2020
|x 1751-7915
856 4 _ |u https://juser.fz-juelich.de/record/872541/files/Rechnung_R-2019-00444.pdf
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/872541/files/Becker%20et%20al%202019%20Microb%20Biotechnol%201-13.pdf
856 4 _ |x pdfa
|u https://juser.fz-juelich.de/record/872541/files/Rechnung_R-2019-00444.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://juser.fz-juelich.de/record/872541/files/Becker%20et%20al%202019%20Microb%20Biotechnol%201-13.pdf?subformat=pdfa
909 C O |o oai:juser.fz-juelich.de:872541
|p openaire
|p open_access
|p OpenAPC
|p driver
|p VDB
|p openCost
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)176653
913 1 _ |a DE-HGF
|b Key Technologies
|l Key Technologies for the Bioeconomy
|1 G:(DE-HGF)POF3-580
|0 G:(DE-HGF)POF3-581
|2 G:(DE-HGF)POF3-500
|v Biotechnology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MICROB BIOTECHNOL : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 p c |a APC keys set
|2 APC
|0 PC:(DE-HGF)0000
915 p c |a Local Funding
|2 APC
|0 PC:(DE-HGF)0001
915 p c |a DFG OA Publikationskosten
|2 APC
|0 PC:(DE-HGF)0002
915 p c |a DOAJ Journal
|2 APC
|0 PC:(DE-HGF)0003
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)IBG-1-20101118
|k IBG-1
|l Biotechnologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)IBG-1-20101118
980 _ _ |a APC
980 1 _ |a APC
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21